Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was down 6% on Tuesday . The stock traded as low as $24.01 and last traded at $24.16. Approximately 31,783 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 205,803 shares. The stock had previously closed at $25.70.

Analysts Set New Price Targets

A number of research firms recently commented on DNTH. Wedbush reduced their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Raymond James upped their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Trading Down 0.9 %

The company has a market cap of $753.62 million, a P/E ratio of -9.66 and a beta of 1.75. The firm’s 50 day moving average price is $26.65 and its 200-day moving average price is $26.53.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. SG Americas Securities LLC grew its holdings in Dianthus Therapeutics by 104.0% during the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after purchasing an additional 4,506 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after acquiring an additional 29,159 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after purchasing an additional 8,473 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.